<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678492</url>
  </required_header>
  <id_info>
    <org_study_id>KY20202114-F-1</org_study_id>
    <nct_id>NCT04678492</nct_id>
  </id_info>
  <brief_title>Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy</brief_title>
  <official_title>Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating efficacy and safety of high-dose esomeprazole and amoxicillin&#xD;
      dual therapy(esomeprazole and amoxicillin) versus bismuth-containing quadruple&#xD;
      Therapy(bismuth，esomeprazole，tetracycline and furazolidone) in H. pylori rescue therapy. It&#xD;
      is hypothesized that high-dose esomeprazole and amoxicillin dual therapy is non-inferior to&#xD;
      bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori&#xD;
      eradication will be randomized to one of the treatments described above. At week 6 follow-up&#xD;
      visits, a urea breath test，rapid urease test or helicobacter pylori stool antigen test will&#xD;
      be performed to confirm eradication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include three phases: screening, treatment and follow-up.&#xD;
&#xD;
      Screening: this phase will last a maximum of 14 days and subjects eligibility will be&#xD;
      evaluated after signing informed consent. One of urea breath test，rapid urease test or&#xD;
      helicobacter pylori stool antigen test will be performed in addition to the baseline routine&#xD;
      evaluations.&#xD;
&#xD;
      Treatment: Subjects are randomly assigned to treatment and will be treated for 14 days. A&#xD;
      randomization visit will take place on Day 0 and an end-of-treatment visit will take place&#xD;
      between day 14 and 16.&#xD;
&#xD;
      Follow-up: includes one visits. Approximately 28 days after the end of treatment. Eradication&#xD;
      of H. Pylori will be confirmed by one of urea breath test，rapid urease test or helicobacter&#xD;
      pylori stool antigen test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>The primary end point of this study is H.pylori eradication，established by negative [13C] urea breath test （DOB value below 3.9）28 days after the end of eradication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptoms effective rates</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>symptoms improvement rates Evaluation improvement rate of symptoms 2 weeks of treatment and 4 weeks after the end of treatment. Symptom improvement rate =#total score before treatment - total score after treatment#/total score before treatment x100%. Total score = frequency + severity.Frequency score is calculated by all the frequency of heartburn, reflux, abdominal pain, and flatulence, etc. Severity is accumulated by the degree of symptoms described above, which is divided to 4 degree as 0 presenting none, and 3 presenting most severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Participants with Adverse Events as a Measure of Safety and Tolerability.The common side effects of the study include headache,dizziness,skin rash,other gastrointestinal disorders,pyrexia,cough and back pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">658</enrollment>
  <condition>Gastritis</condition>
  <condition>Dyspepsia</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Gastric Cancer</condition>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>High-dose esomeprazole and amoxicillin dual therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole 40 mg and amoxicillin 1000 mg by mouth，three time daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bismuth-containing quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tetracycline 500mg three time daily for 14 days，furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID</description>
    <arm_group_label>High-dose esomeprazole and amoxicillin dual therapy</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID</description>
    <arm_group_label>High-dose esomeprazole and amoxicillin dual therapy</arm_group_label>
    <other_name>Amoxy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth</intervention_name>
    <description>Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID</description>
    <arm_group_label>Bismuth-containing quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID</description>
    <arm_group_label>Bismuth-containing quadruple therapy</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline</intervention_name>
    <description>Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID</description>
    <arm_group_label>Bismuth-containing quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furazolidone</intervention_name>
    <description>Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID</description>
    <arm_group_label>Bismuth-containing quadruple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who had failed H.pylori eradication therapies before.&#xD;
&#xD;
          2. Age between 18~70, both gender.&#xD;
&#xD;
          3. Patients who had failed H.pylori eradication therapies during last 2 years and stop&#xD;
             the eradication therapies for at least 3 months.&#xD;
&#xD;
          4. Women are eligible if they are not pregnant or nursing, and if they are of&#xD;
             childbearing potential they are required to use medically acceptable contraception for&#xD;
             the duration of the study and 30 days thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are excluded if they have previously used tetracycline and furazolidone&#xD;
             antibiotics to eradicate infection with H. pylori.&#xD;
&#xD;
          2. Contraindications to study drugs.&#xD;
&#xD;
          3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.&#xD;
&#xD;
          4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI)&#xD;
             within 2 weeks before the [13C] urea breath test), antibiotics or bismuth complexes&#xD;
             (more than 3 times /1 month before screening).&#xD;
&#xD;
          5. Pregnant or lactating women.&#xD;
&#xD;
          6. Underwent upper gastrointestinal Surgery.&#xD;
&#xD;
          7. Patients with moderate or severe atypical hyperplasia or high-grade intraepithelial&#xD;
             neoplasia.&#xD;
&#xD;
          8. have symptom of dysphagia.&#xD;
&#xD;
          9. Evidence of bleeding or iron efficiency anemia.&#xD;
&#xD;
         10. A history of malignancy.&#xD;
&#xD;
         11. Drug or alcohol abuse history in the past 1 year.&#xD;
&#xD;
         12. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,&#xD;
             anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less&#xD;
             than 100 mg/d).&#xD;
&#xD;
         13. a person with a mental disorder.&#xD;
&#xD;
         14. Enrolled in other clinical trials in the past 3 months.&#xD;
&#xD;
         15. Refuse to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hosipital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Yongquan Shi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>High-dose dual therapy</keyword>
  <keyword>Bismuth-combining quadruple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Furazolidone</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

